Medigene Full Year 2023 Earnings: Beats Expectations

Medigene (ETR:MDG1) Full Year 2023 Results

Key Financial Results

• Revenue: €6.03m (down 81% from FY 2022).
• Net loss: €16.2m (loss widened by 94% from FY 2022).
• €0.66 loss per share (further deteriorated from €0.34 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Medigene Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates by 16%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Germany.

Performance of the German Biotechs industry.

The company's shares are down 10% from a week ago.

Risk Analysis

Before you take the next step you should know about the 4 warning signs for Medigene (2 make us uncomfortable!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.